| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee2b4cf5180521e069e04d91bced4ff1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6903
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2003-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e9efa1dbc39c4d39710c4449df7a86a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3410aa2303db27740b02324cec2b312
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c73c76ec496dc64f965cab329af3914
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49f52a7a4d4a2ee936722dd2dcdb9e5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_369e14851097cf26ecfb09c52732b78a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53cfe270f6644a727df1c61bc32653cb |
| publicationDate |
2012-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2387072-T3 |
| titleOfInvention |
Tumor-specific recognition molecules |
| abstract |
Pharmaceutical or diagnostic composition comprising a characterizing recognition molecule comprising an amino acid sequence containing (i) an amino acid sequence that is at least 80% homologous to the amino acid sequence shown in SEQ ID NO: 1 and (ii) a amino acid sequence that is at least 80% homologous to the amino acid sequence shown in SEQ ID No. 2 or 3 and (iii) an amino acid sequence that is at least 80% homologous to the amino acid sequence SEC ID No. 4, 5 or 6 and which specifically binds to the Core-1 antigen, wherein said pharmaceutical composition optionally comprises a pharmaceutically acceptable carrier and / or diluent. |
| priorityDate |
2002-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |